Literature DB >> 15280830

A complete and durable clinical response to high-dose dexamethasone in a patient with scleromyxedema.

Keren B Horn1, Meyer A Horn, James Swan, Seema Singhal, Joan Guitart.   

Abstract

We report a case of a patient with scleromyxedema limited to the skin with an associated IgG lambda monoclonal protein treated successfully with high-dose dexamethasone. We encourage the continued investigation of this complex relationship between the clinical presentation of scleromyxedema and its frequently associated paraproteinemia.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15280830     DOI： 10.1016/j.jaad.2004.03.023

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN： 0190-9622            Impact factor:   11.527


  5 in total

Review 1.  Cutaneous Manifestations of Scleroderma and Scleroderma-Like Disorders: a Comprehensive Review.

Authors:  Caterina Ferreli; Giulia Gasparini; Aurora Parodi; Emanuele Cozzani; Franco Rongioletti; Laura Atzori
Journal:  Clin Rev Allergy Immunol       Date:  2017-12       Impact factor: 8.667

2.  [Scleromyxedema].

Authors:  G Kukova; D Bruch-Gerharz; K Gensch; T Ruzicka; J Reifenberger
Journal:  Hautarzt       Date:  2006-04       Impact factor: 0.751

3.  [Scleromyxedema. A chronic progressive systemic disease].

Authors:  A Kreuter; M Stücker; A G A Kolios; P Altmeyer; K Möllenhoff
Journal:  Z Rheumatol       Date:  2012-08       Impact factor: 1.372

Review 4.  [Scleromyxedema].

Authors:  M Neufeld; C Sunderkötter; R K C Moritz
Journal:  Hautarzt       Date:  2018-11       Impact factor: 0.751

Review 5.  New insights on scleromyxedema.

Authors:  Laura Atzori; Caterina Ferreli; Franco Rongioletti
Journal:  J Scleroderma Relat Disord       Date:  2019-01-29
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.